RT Journal Article
SR Electronic
T1 Microarray-based mRNA Expression Profiling of Leukemia Cells Treated with the Flavonoid, Casticin
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 143
OP 151
VO 9
IS 3
A1 RIGHESCHI, CHIARA
A1 EICHHORN, TOLGA
A1 KARIOTI, ANASTASIA
A1 BILIA, ANNA RITA
A1 EFFERTH, THOMAS
YR 2012
UL http://cgp.iiarjournals.org/content/9/3/143.abstract
AB Natural polyphenols play an important role in tumor inhibition. We used a doxorubicin-sensitive acute T-lymphoblastic leukemia cell line (CCRF-CEM) and its multidrug-resistant subline (CEM/ADR5000) to evaluate the activity of 15 plant polyphenols isolated in our laboratory (hypericin and pseudohypericin, verbascoside, ellagic acid, casticin, kaempferol-3-O-(2’’,6’’-di-E-p-coumaroyl)-glucopyranoside, kaempferol-3-O-(3,4-diacetyl-2,6-di-E-p-coumaroyl) -glucopyranoside, tiliroside, salvianolic acid B, oleuropein, rosmarinic acid, bergenin) or of others from commercial sources (curcumin, epigallocatechin-3-gallate, silymarin). Casticin was the most potent compound (IC50 values of 0.28±0.02 μM in CCRF-CEM and 0.44±0.17 μM in CEM/ADR5000 cells. The IC50 values of the other compounds tested ranged from 1.52 μM to 164.1 μM. A microarray-based mRNA expression profiling of CCRF-CEM cells treated with casticin was performed in order to identify genes with altered expression following casticin treatment. Networks related to NF-κB, p38MAPK, histones H3 and H4, and follicle stimulating hormone were identified.